It is estimated that the worldwide prevalence of AAE ranges from 1 person in every 10,000 people are affected to 1 case in every 150,000 people. However, it is thought that this disease prevalence could be higher due to diagnostic oversight and the shared symptoms of<unk>  angioedema with similar diseases. This disease tends to affect males and females equally. Additionally, individuals with<unk>  angioedema usually develops symptoms in their fourth decade of life or older. Of note, Saini reports the difficulty of diagnosing angioedema accurately due to certain challenges. These obstacles include the lack of awareness about angioedema presentation and potentially higher than expected worldwide prevalence. More challenges include the similarities to paraneoplastic disorders that often require higher priority of care, the evolution of symptoms over time, and mild cases might be attributed to medication use or allergic reactions from an individual's existing medical history. As a result, accurate diagnosis of AAE can take several months, which can delay targeted and specific treatment.
Acquired C1 esterase inhibitor deficiency
Hereditary angioedema
Terminal complement pathway deficiency
Type IV hypersensitivity
IgG4-related skin disease
Complement 3 deficiency
Type III hypersensitivity
Complement 2 deficiency